HTG Molecular Diagnostics Inc (NASDAQ:HTGM) dropped 1.2% on Thursday . The stock traded as low as $2.31 and last traded at $2.44, with a volume of 96,773 shares. The stock had previously closed at $2.47.

HTGM has been the subject of several research analyst reports. Zacks Investment Research downgraded shares of HTG Molecular Diagnostics from a “hold” rating to a “sell” rating in a report on Wednesday, April 27th. Canaccord Genuity reaffirmed a “buy” rating and issued a $6.00 price objective on shares of HTG Molecular Diagnostics in a report on Friday, May 13th.

The firm has a 50 day moving average of $2.49 and a 200-day moving average of $2.71. The company’s market capitalization is $17.20 million.

HTG Molecular Diagnostics (NASDAQ:HTGM) last issued its earnings results on Tuesday, August 9th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.95) by $0.03. On average, analysts forecast that HTG Molecular Diagnostics Inc will post ($3.82) EPS for the current fiscal year.

HTG Molecular Diagnostics, Inc is a provider of instruments and reagents for molecular profiling applications. The Company has developed and markets a technology platform for the routine use of complex molecular profiling. The Company’s HTG Edge platform, consisting of instrumentation, including HTG Edge and HTG EdgeSeq systems, consumables and software analytics, is used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.